Bioanalytical labs need to reimagine data to streamline their operations

The fundamental questions in the trial phases of drug development are “Does it work?”, “Is it safe?”, and “What else do we need to know?”

These questions can only be answered thanks to bioanalytical labs. The tests that these labs run every day on samples from clinical trials are essential in understanding which drugs and therapeutics will ultimately benefit patients.

The faster scientists are able to make decisions, the faster new drugs can come to market. To facilitate these decisions, scientists need reliable and quality data. Whether labs are housed in sponsor organizations or in contract research organizations (CROs), the underlying challenge is the same: How do we test more samples in less time, without sacrificing accuracy and quality?

Read the full article on the pharmaphorum website.

About the author

Kevin Tse is an account manager at IDBS. Kevin leverages extensive industry experience and product expertise to identify value-added solutions to each business’ unique challenges and goals.
Prior to joining IDBS, Kevin held a variety of bioanalytical roles in preclinical research, analytical development and quality control within the biopharmaceutical industry.
Kevin holds a BSc in Biology from University of Massachusetts Amherst and a MSc Bioscience Administration from Worcester Polytechnic Institute.